Business
UKE publishes evaluation of Parsortix
UKE publishes evaluation of Parsortix.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 8247M Angle PLC 25 January 2016 \n\n\n\n\n\nFor immediate release \n \n\n\n25 January 2016\n\n\n\n\nANGLE plc \n(\"ANGLE\" or \"the Company\")\n \nPEER-REVIEWED PUBLICATION HIGHLIGHTS SIGNIFICANT ADVANTAGES OF PARSORTIXTM IN HARVESTING CTCS OVER OTHER APPROACHES \n \nAllows Harvesting of Cancer Cells From Blood With Exceptional Purity And Viability Enabling Broad Range Of Molecular Analysis \n \nPaper by University Medical Centre Hamburg-Eppendorf (UKE) published in International Journal of Cancer\n \nANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, today announces that University Medical Centre Hamburg-Eppendorf (UKE) has published an evaluation of ANGLE's ParsortixTM system in the prestigious peer-reviewed International Journal of Cancer. The paper is entitled \"A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells\" 1. \n \nThe UKE cancer research centre is a world-leading authority on the emerging field of liquid biopsy and, in 2015 alone, published 17 scientific papers in high ranking journals on different aspects of the application of liquid biopsy in cancer care. \n \nUKE's evaluation demonstrated significant advantages of the Parsortix system in harvesting circulating tumour cells (CTCs) compared to antibody-based and filtration CTC enrichment systems. The publication determined that the Parsortix system enables the harvesting of CTCs at a high purity and provides viable tumour cells that are easily accessible and ready for a broad range of molecular and functional analyses. \n \n99 per cent of the harvested CTCs from both spiked and patient samples were viable after processing and still functional for downstream molecular analysis as demonstrated by mRNA characterisation and array based comparative genomic hybridisation. \n \nProf. Klaus Pantel, Chairman, Department of Tumour Biology at UKE's Centre of Experimental Medicine, commented:\n \n\"Systems that can comprehensively capture the broad range of CTCs - not only epithelial cells, but others including mesenchymal cells - will play an important role in cancer diagnoses and subsequent treatment. Our findings emphasise the importance of developing new label-free a...